StockNews.com Begins Coverage on DBV Technologies (NASDAQ:DBVT)

Investment analysts at StockNews.com began coverage on shares of DBV Technologies (NASDAQ:DBVT) in a research note issued to investors on Thursday. The firm set a “hold” rating on the stock.

Several other equities analysts also recently commented on the stock. JMP Securities restated a “market outperform” rating and issued a $5.00 price target on shares of DBV Technologies in a research note on Tuesday, September 24th. HC Wainwright upped their price target on DBV Technologies from $5.00 to $7.00 and gave the stock a “buy” rating in a report on Thursday, October 24th.

DBV Technologies Price Performance

Shares of DBVT opened at $0.59 on Thursday. The firm has a 50-day simple moving average of $0.73 and a two-hundred day simple moving average of $0.89. DBV Technologies has a 1-year low of $0.50 and a 1-year high of $2.14. The stock has a market cap of $57.22 million, a PE ratio of -0.65 and a beta of 0.66.

DBV Technologies’s stock is going to reverse split before the market opens on Friday, November 29th. The 1-5 reverse split was announced on Monday, November 11th. The number of shares owned by shareholders will be adjusted after the market closes on Thursday, November 28th.

Hedge Funds Weigh In On DBV Technologies

An institutional investor recently raised its position in DBV Technologies stock. Yiheng Capital Management L.P. raised its holdings in shares of DBV Technologies S.A. (NASDAQ:DBVT) by 6.2% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 5,568,909 shares of the company’s stock after acquiring an additional 327,345 shares during the quarter. DBV Technologies makes up 0.2% of Yiheng Capital Management L.P.’s investment portfolio, making the stock its 15th biggest holding. Yiheng Capital Management L.P. owned about 2.89% of DBV Technologies worth $4,172,000 as of its most recent SEC filing. 71.74% of the stock is currently owned by institutional investors.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.